Category Archives: Investment

Netherlands-based, emerging biotech star arGEN-X gives shareholders two doses of great news; stock skyrockets.

The News: arGEN-X SE (Breda NLD) has smoked its target of $150 million for a US stock offering, which will support its cancer and autoimmune disease antibodies through the clinical phases…. Read more »

Micro biotech Alzinova, hiding out in southwest Sweden, using proprietary peptide technology that targets key Alzheimer’s toxins.

Background: Alzinova AB (Gothenburg) is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease (AD). The company was founded in 2011… Read more »

From across the pond, 2017’s brightest European biotech stars; perhaps under US’s radar, but still ready to soar?

Many said good riddance to 2016 for biotech and pharma; things could only get better this year–and the European industry didn’t disappoint, says Labiotech.eu, the quintessential industry observer and news… Read more »

Tiny Scottish biotech TauRx lobs bomb into Alzheimer’s fracas with Phase 3 success.

The News: After countless failures, the race for a treatment saw obscure TauRx Therapeutics Ltd. (Aberdeen Scotland) sprint ahead as its Alzheimer’s drug candidate prevented the formation of Tau tangles that… Read more »

Weekly medical stock spotlight: Buy, wait or run? Leaders = Otonomy, Collegium & Sage; Laggards = Selecta & Tivity.

1.Otonomy Inc. (Nasdaq:OTIC) led advancing issues last week, rocketing 73% to $5.17. A Phase 3 clinical trial (AVERTS-2) assessing Otonomy’s Otividex in patients with Ménière’s disease, achieved its primary endpoint of the… Read more »

What’s wrong with Celgene as shares get clobbered? Nothing, actually.

The News: Celgene Corp. (Summit NJ) plummeted 20% Thursday (October 26, 2017) to $99.99 after releasing third-quarter earnings. And it wasn’t so much third-quarter revenue, which was up 10% year over year,… Read more »

MannKind’s 10-year quest for insulin product Afrezza gets last-ditch chance; time to buy, or run?

The News: Last week, MannKind Corp. (Nasdaq:MNKD) led advancing stocks in the healthcare sector, soaring 151% to $5.03, after saying it won a labeling concession from the FDA on its Afrezza inhalable… Read more »

Catabasis soars on fresh Duchenne trial data, proving biotech melt-up still in progress; but for how much longer?

The News: Recuperating from a trial flop involving its lead drug for Duchenne muscular dystrophy, Catabasis Pharmaceuticals Inc. (Cambridge MA) is charging ahead with a late-stage study, hyping new data… Read more »

Senators seek probe of Allergan’s patent sale to Mohawk Tribe; could Tesla do the same with its battery patents?

The News: Four senators are demanding an investigation of Allergan PLC’s (Dublin IRL) first-of-a-kind patent deal with the Saint Regis Mohawk Tribe, alleging the move to protect Restasis is another… Read more »